• Explore /
  • Poster
  • / Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors.

Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors.

Abstract Poster

Authors

Ginna Laport

Ginna Laport

Tempest Therapeutics, San Francisco, CA

Ginna Laport , John D. Powderly II, Saurin Chokshi , Jason J. Luke , Johanna C. Bendell , Amanda Enstrom , Chan C Whiting , Thomas Walter Dubensky Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT03829436

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2665)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2665

Abstract #

TPS2665

Poster Bd #

298b

Abstract Disclosures

Similar Posters

First Author: Jin Li

First Author: Filip Janku

First Author: Desamparados Roda

First Author: Iwona A. Lugowska